SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: stockdoc77 who wrote (50134)2/8/2019 6:10:30 AM
From: patlawche11  Read Replies (1) of 63285
 
>and that the P3 trial doesn't report a negative result, which destroys the company<

Isn't the Ascent P3 an open-label, randomized trial. If so, wouldn't IMMU have a sense of whether or not 132 was showing improved efficacy over the control (maybe not with full statistical analysis) well ahead of 2020, especially if they are planning or allowed an interim look, and to use this information for business purposes?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News